IT - EN
Pharmaceutical Operations

Pharmaceutical OperationsR & DPipeline

NAME ORIGINATOR INDICATION DEVELOPMENT STATUS
CYSTADROPS® Recordati Corneal cysteine crystal deposits in patients with cystinosis Approved in EU in January 2017
FORTACIN™ Plethora Solutions Premature ejaculation Marketing authorization trasferred to Recordati
REAGILA® Gedeon Richter Schizophrenia Approved in EU
methadone   Treatment of cancer-related pain in cases of resistance or intolerance to opioids Under review in France
GRASPA® Erytech Acute lymphoblastic leukemia (ALL) in patients with first recurrence of Philadelphia chromosome negative ALL
 
Acute myeloid leukemia (AML) in patients >65 unfit for chemotherapy
Filed in EU
 
 
 
Phase II b
CARBAGLU® Recordati Hyperammonaemia due to NAGS deficiency and to the main organic acidemias Development of new formulations in EU and USA
Pre-filing in the USA for the organic acidemias indication
REC 0551 Recordati/Meyer Hospital (Florence) Retinopathy of Prematurity (ROP) Formulation development
Phase II in Italy
REC 0438 Recordati/UFPeptides Overactive bladder in patients with spinal lesions Proof of concept  planning in EU
REC 0559 Recordati/Mime Tech Neurotrophic keratitis Formulation development
Clinical development planning
REC 0545 Recordati AP-HP Acute decompensation episodes in MSUD Formulation development
Clinical development planning